Clobetasol
 Clobetasol Cream

drug-information.ru

|Clobetasol Clobetasol Cream

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Clobetasol


Generic Name: Clobetasol propionate
Dosage Form: Gel, cream, ointment

Rx Only

FOR DERMATOLOGIC USE ONLY

NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE

Clobetasol Description

Clobetasol propionate gel, cream and ointment contain the active compound Clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity.

Clobetasol propionate is a white to cream-colored crystalline powder insoluble in water. Chemically, it is 21-chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate, and it has the following structural formula:

Each gram of the 0.05% gel contains 0.5 mg Clobetasol propionate in a base of propylene glycol, carbomer 934P, sodium hydroxide and purified water.

Each gram of the 0.05% cream contains Clobetasol propionate 0.5 mg in a cream base of propylene glycol, glyceryl monostearate, cetostearyl alcohol, glyceryl stearate, PEG 100 stearate, white wax, chlorocresol, sodium citrate anhydrous, citric acid anhydrous, and purified water.

Each gram of the 0.05% ointment contains Clobetasol propionate 0.5 mg in a base of propylene glycol, sorbitan sesquioleate, and white petrolatum.

Clobetasol - Clinical Pharmacology

Like other topical corticosteroids, Clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours has not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Greater absorption was observed for the Clobetasol propionate gel formulation as compared to the cream formulation in in vitro human skin penetration studies. Studies performed with Clobetasol propionate gel, cream and ointment indicate that they are in the super-high range of potency as compared with other topical corticosteroids.

Indications and Usage for Clobetasol

Clobetasol propionate gel, cream and ointment are super-high potency corticosteroid formulations indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in children under 12 years of age is not recommended. As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.

Contraindications

Clobetasol propionate gel, cream and ointment are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Precautions

General: Clobetasol propionate is a highly potent topical corticosteroid that has been shown to suppress the HPA axis at doses as low as 2 g per day.

Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal from treatment. Manifestations of Cushing"s syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on therapy.

Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppression. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.

Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (see PRECAUTIONS: Pediatric Use).

If irritation develops, Clobetasol propionate should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing. If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Clobetasol propionate should be discontinued until the infection has been adequately controlled.

Clobetasol propionate gel, cream and ointment should not be used in the treatment of rosacea or perioral dermatitis and it should not be used on the face, groin, or axillae.

Information for Patients: Patients using topical corticosteroids should receive the following information and instructions:

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
  2. This medication should not be used for any disorder other than that for which it was prescribed.
  3. The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician.
  4. Patients should report any signs of local adverse reactions to the physician.
  5. Patients should inform their physicians that they are using Clobetasol propionate if surgery is contemplated.

Laboratory Tests: The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test, A.M. plasma cortisol test, Urinary free cortisol test.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential of Clobetasol propionate. Studies in the rat following oral administration at dosage levels up to 50 mg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose. Clobetasol propionate was non-mutagenic in three different test systems: the Ames test, the Saccharomyces cerevisiae gene conversion assay, and the E. coli B WP2 fluctuation test.

Pregnancy:Teratogenic Effects–Pregnancy Category C. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application to laboratory animals. Clobetasol propionate has not been tested for teratogenicity when applied topically; however, it is absorbed percutaneously, and when administered subcutaneously it was a significant teratogen in both the rabbit and mouse. Clobetasol propionate has greater teratogenic potential than steroids that are less potent. Teratogenicity studies in mice using the subcutaneous route resulted in fetotoxicity at the highest dose tested (1 mg/kg) and teratogenicity at all dose levels tested down to 0.03 mg/kg. These doses are approximately 0.33 and 0.01 times, respectively, the human topical dose of Clobetasol propionate gel, cream and ointment. Abnormalities seen included cleft palate and skeletal abnormalities. In rabbits, Clobetasol propionate was teratogenic at doses of 3 and 10 mcg/kg. These doses are approximately 0.001 and 0.003 times, respectively, the human topical dose of Clobetasol propionate gel, cream and ointment. Abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities. In rabbits, Clobetasol propionate given by the same route was teratogenic at doses of 3 and 10 mcg/kg. These doses are approximately 0.001 and 0.003 times, respectively, the human topical dose of Clobetasol propionate gel. Abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities. There are no adequate and well-controlled studies of the teratogenic potential of Clobetasol propionate in pregnant women. Clobetasol propionate gel, cream and ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when either Clobetasol propionate gel, cream and ointment is administered to a nursing woman.

Pediatric Use: Safety and effectiveness of Clobetasol propionate gel, cream and ointment in pediatric patients have not been established. Use in children under 12 years of age is not recommended. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing"s syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children (see PRECAUTIONS).

HPA axis suppression, Cushing"s syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels, and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Geriatric Use: Clinical studies of Clobetasol propionate drug products in US clinical trials did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious.

Adverse Reactions

In a controlled clinical trial with Clobetasol propionate gel, the only reported adverse reaction that was considered to be drug related was a report of burning sensation (1.8% of treated patients). In controlled clinical trials, the most frequent adverse reactions reported for Clobetasol propionate cream were burning and stinging sensation in 1% of treated patients. Less frequent adverse reactions were itching, skin atrophy, and cracking and fissuring of the skin. In controlled clinical trials, the most frequent adverse events reported for Clobetasol propionate ointment were burning sensation, irritation, and itching in 0.5% of treated patients. Less frequent adverse reactions were stinging, cracking, erythema, folliculitis, numbness of fingers, skin atrophy, and telangiectasia.

Cushing"s syndrome has been reported in infants and adults as a result of prolonged use of topical Clobetasol propionate formulations. The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: dryness, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, and miliaria.

Overdosage

Topically applied Clobetasol propionate gel, cream and ointment can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).

Clobetasol Dosage and Administration

Apply a thin layer of Clobetasol propionate gel, cream or ointment to the affected skin areas twice daily and rub in gently and completely. (See INDICATIONS AND USAGE.)

Clobetasol propionate gel, cream and ointment are super-high potency topical corticosteroids; therefore, treatment should be limited to 2 consecutive weeks, and amounts greater than 50 g per week should not be used.

As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.

Clobetasol propionate gel, cream and ointment should not be used with occlusive dressings.

How is Clobetasol Supplied

Clobetasol Propionate Gel, 0.05% is supplied in tamper-evident tubes as follows:

15 g (NDC 0168-0293-15) 30 g (NDC 0168-0293-30)
60 g (NDC 0168-0293-60)

Clobetasol Propionate Cream USP, 0.05% is supplied in tamper-evident tubes as follows:

15 g (NDC 0168-0163-15) 30 g (NDC 0168-0163-30)
45 g (NDC 0168-0163-46) 60 g (NDC 0168-0163-60)

Clobetasol Propionate Ointment USP, 0.05% is supplied in tamper-evident tubes as follows:

15 g (NDC 0168-0162-15) 30 g (NDC 0168-0162-30)
45 g (NDC 0168-0162-46) 60 g (NDC 0168-0162-60)

Store at controlled room temperature 15°-30°C (59°-86°F). DO NOT REFRIGERATE

E. FOUGERA & CO.
a division of Altana Inc.
MELVILLE, NEW YORK 11747

I2162E
R10/05
#202


Clobetasol Propionate (Clobetasol Propionate)
PRODUCT INFO
Product Code 0168-0293 Dosage Form GEL
Route Of Administration TOPICAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Clobetasol propionate (Clobetasol) Active 0.5 MILLIGRAM  In 1 GRAM
propylene glycol Inactive  
carbomer 934P Inactive  
sodium hydroxide Inactive  
water Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0168-0293-15 15 GRAM In 1 TUBE None
2 0168-0293-30 30 GRAM In 1 TUBE None
3 0168-0293-60 60 GRAM In 1 TUBE None

Clobetasol Propionate (Clobetasol Propionate)
PRODUCT INFO
Product Code 0168-0163 Dosage Form CREAM
Route Of Administration TOPICAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Clobetasol propionate (Clobetasol) Active 0.5 MILLIGRAM  In 1 GRAM
propylene glycol Inactive  
glyceryl monostearate Inactive  
cetostearyl alcohol Inactive  
glyceryl stearate Inactive  
PEG 100 stearate Inactive  
white wax Inactive  
chlorocresol Inactive  
sodium citrate anhydrous Inactive  
citric acid anhydrous Inactive  
water Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0168-0163-15 15 GRAM In 1 TUBE None
2 0168-0163-30 30 GRAM In 1 TUBE None
3 0168-0163-46 45 GRAM In 1 TUBE None
4 0168-0163-60 60 GRAM In 1 TUBE None

Clobetasol Propionate (Clobetasol Propionate)
PRODUCT INFO
Product Code 0168-0162 Dosage Form OINTMENT
Route Of Administration TOPICAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Clobetasol propionate (Clobetasol) Active 0.5 MILLIGRAM  In 1 GRAM
propylene glycol Inactive  
sorbitan sesquioleate Inactive  
white petrolatum Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0168-0162-15 15 GRAM In 1 TUBE None
2 0168-0162-30 30 GRAM In 1 TUBE None
3 0168-0162-46 45 GRAM In 1 TUBE None
4 0168-0162-60 60 GRAM In 1 TUBE None

Revised: 04/2007





Where can I get more information about Clobetasol Clobetasol Cream ? We recommend to use www.Drugs.com

Typical mistypes for Clobetasol Clobetasol Cream
xlobetasol clobetasol cream, vlobetasol clobetasol cream, flobetasol clobetasol cream, dlobetasol clobetasol cream, ckobetasol clobetasol cream, cpobetasol clobetasol cream, coobetasol clobetasol cream, clibetasol clobetasol cream, clkbetasol clobetasol cream, cllbetasol clobetasol cream, clpbetasol clobetasol cream, cl0betasol clobetasol cream, cl9betasol clobetasol cream, clovetasol clobetasol cream, clonetasol clobetasol cream, clohetasol clobetasol cream, clogetasol clobetasol cream, clobwtasol clobetasol cream, clobstasol clobetasol cream, clobdtasol clobetasol cream, clobrtasol clobetasol cream, clob4tasol clobetasol cream, clob3tasol clobetasol cream, cloberasol clobetasol cream, clobefasol clobetasol cream, clobegasol clobetasol cream, clobeyasol clobetasol cream, clobe6asol clobetasol cream, clobe5asol clobetasol cream, clobetzsol clobetasol cream, clobetssol clobetasol cream, clobetwsol clobetasol cream, clobetqsol clobetasol cream, clobetaaol clobetasol cream, clobetazol clobetasol cream, clobetaxol clobetasol cream, clobetadol clobetasol cream, clobetaeol clobetasol cream, clobetawol clobetasol cream, clobetasil clobetasol cream, clobetaskl clobetasol cream, clobetasll clobetasol cream, clobetaspl clobetasol cream, clobetas0l clobetasol cream, clobetas9l clobetasol cream, clobetasok clobetasol cream, clobetasop clobetasol cream, clobetasoo clobetasol cream, clobetasol xlobetasol cream, clobetasol vlobetasol cream, clobetasol flobetasol cream, clobetasol dlobetasol cream, clobetasol ckobetasol cream, clobetasol cpobetasol cream, clobetasol coobetasol cream, clobetasol clibetasol cream, clobetasol clkbetasol cream, clobetasol cllbetasol cream, clobetasol clpbetasol cream, clobetasol cl0betasol cream, clobetasol cl9betasol cream, clobetasol clovetasol cream, clobetasol clonetasol cream, clobetasol clohetasol cream, clobetasol clogetasol cream, clobetasol clobwtasol cream, clobetasol clobstasol cream, clobetasol clobdtasol cream, clobetasol clobrtasol cream, clobetasol clob4tasol cream, clobetasol clob3tasol cream, clobetasol cloberasol cream, clobetasol clobefasol cream, clobetasol clobegasol cream, clobetasol clobeyasol cream, clobetasol clobe6asol cream, clobetasol clobe5asol cream, clobetasol clobetzsol cream, clobetasol clobetssol cream, clobetasol clobetwsol cream, clobetasol clobetqsol cream, clobetasol clobetaaol cream, clobetasol clobetazol cream, clobetasol clobetaxol cream, clobetasol clobetadol cream, clobetasol clobetaeol cream, clobetasol clobetawol cream, clobetasol clobetasil cream, clobetasol clobetaskl cream, clobetasol clobetasll cream, clobetasol clobetaspl cream, clobetasol clobetas0l cream, clobetasol clobetas9l cream, clobetasol clobetasok cream, clobetasol clobetasop cream, clobetasol clobetasoo cream, clobetasol clobetasol xream, clobetasol clobetasol vream, clobetasol clobetasol fream, clobetasol clobetasol dream, clobetasol clobetasol ceeam, clobetasol clobetasol cdeam, clobetasol clobetasol cfeam, clobetasol clobetasol cteam, clobetasol clobetasol c5eam, clobetasol clobetasol c4eam, clobetasol clobetasol crwam, clobetasol clobetasol crsam, clobetasol clobetasol crdam, clobetasol clobetasol crram, clobetasol clobetasol cr4am, clobetasol clobetasol cr3am, clobetasol clobetasol crezm, clobetasol clobetasol cresm, clobetasol clobetasol crewm, clobetasol clobetasol creqm, clobetasol clobetasol crean, clobetasol clobetasol creak, clobetasol clobetasol creaj, lobetasol clobetasol cream, cobetasol clobetasol cream, clbetasol clobetasol cream, cloetasol clobetasol cream, clobtasol clobetasol cream, clobeasol clobetasol cream, clobetsol clobetasol cream, clobetaol clobetasol cream, clobetasl clobetasol cream, clobetaso clobetasol cream, clobetasol clobetasol cream, clobetasol clobetasol cream, clobetasol lobetasol cream, clobetasol cobetasol cream, clobetasol clbetasol cream, clobetasol cloetasol cream, clobetasol clobtasol cream, clobetasol clobeasol cream, clobetasol clobetsol cream, clobetasol clobetaol cream, clobetasol clobetasl cream, clobetasol clobetaso cream, clobetasol clobetasolcream, clobetasol clobetasol ream, clobetasol clobetasol ceam, clobetasol clobetasol cram, clobetasol clobetasol crem, clobetasol clobetasol crea, lcobetasol clobetasol cream, colbetasol clobetasol cream, clboetasol clobetasol cream, cloebtasol clobetasol cream, clobteasol clobetasol cream, clobeatsol clobetasol cream, clobetsaol clobetasol cream, clobetaosl clobetasol cream, clobetaslo clobetasol cream, clobetaso l clobetasol cream, clobetasol clobetasol cream, clobetasol c lobetasol cream, clobetasol lcobetasol cream, clobetasol colbetasol cream, clobetasol clboetasol cream, clobetasol cloebtasol cream, clobetasol clobteasol cream, clobetasol clobeatsol cream, clobetasol clobetsaol cream, clobetasol clobetaosl cream, clobetasol clobetaslo cream, clobetasol clobetaso lcream, clobetasol clobetasolc ream, clobetasol clobetasol rceam, clobetasol clobetasol ceram, clobetasol clobetasol craem, clobetasol clobetasol crema, cclobetasol clobetasol cream, cllobetasol clobetasol cream, cloobetasol clobetasol cream, clobbetasol clobetasol cream, clobeetasol clobetasol cream, clobettasol clobetasol cream, clobetaasol clobetasol cream, clobetassol clobetasol cream, clobetasool clobetasol cream, clobetasoll clobetasol cream, clobetasol clobetasol cream, clobetasol clobetasol cream, clobetasol cclobetasol cream, clobetasol cllobetasol cream, clobetasol cloobetasol cream, clobetasol clobbetasol cream, clobetasol clobeetasol cream, clobetasol clobettasol cream, clobetasol clobetaasol cream, clobetasol clobetassol cream, clobetasol clobetasool cream, clobetasol clobetasoll cream, clobetasol clobetasol cream, clobetasol clobetasol ccream, clobetasol clobetasol crream, clobetasol clobetasol creeam, clobetasol clobetasol creaam, clobetasol clobetasol creamm, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved